Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29942
Title: Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
Authors: Vermersch, P.
Eralinna, J. -P.
Nicholas, R.
Oreja-Guevara, C.
Siva, A.
VAN WIJMEERSCH, Bart 
Wiendl, H.
Buffels, R.
Kuhelj, R.
Wei, W.
Comi, G.
Issue Date: 2019
Publisher: SAGE PUBLICATIONS LTD
Source: MULTIPLE SCLEROSIS JOURNAL, 25(SI), p. 344-345 (Art N° P690)
Notes: [Vermersch, P.] Univ Lille, Lille, France. [Eralinna, J. -P.] NEO Res, Turku, Finland. [Nicholas, R.] Imperial Coll Healthcare NHS Trust, London, England. [Nicholas, R.] Imperial Coll, London, England. [Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain. [Siva, A.] Istanbul Univ, Cerrahpasa Sch Med, Cerrahpasa, Turkey. [Van Wijmeersch, B.] Univ Hasselt, Overpelt, Belgium. [Van Wijmeersch, B.] Rehabil & MS Ctr Overpelt, Overpelt, Belgium. [Wiendl, H.] Univ Munster, Munster, Germany. [Buffels, R.; Kuhelj, R.; Wei, W.] F Hoffmann La Roche Ltd, Basel, Switzerland. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.
Keywords: Clinical Neurology; Neurosciences
Document URI: http://hdl.handle.net/1942/29942
ISSN: 1352-4585
e-ISSN: 1477-0970
ISI #: 000485303101246
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

WEB OF SCIENCETM
Citations

1
checked on May 22, 2022

Page view(s)

42
checked on May 28, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.